Cell cycle regulator MYBL2 is a distinct vulnerability in acute myeloid leukemia

Acute myeloid leukemia (AML) is a hematologic malignancy characterized by the accumulation of myeloid blasts in the bone marrow. Despite the availability of potential curative treatments, patients frequently experience unfavorable outcomes. One crucial aspect contributing to relapse is the plasticit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Küchler, Sandra (VerfasserIn) , Brilloff, Silke (VerfasserIn) , Schäfer, Silvia Maria (VerfasserIn) , Rahimian, Elahe (VerfasserIn) , Kufrin, Vida (VerfasserIn) , Peri, Shraddha S. (VerfasserIn) , Musa, Julian (VerfasserIn) , Grünewald, Thomas G. P. (VerfasserIn) , Schewe, Denis M. (VerfasserIn) , Ball, Claudia R. (VerfasserIn) , Bornhaeuser, Martin (VerfasserIn) , Glimm, Hanno (VerfasserIn) , Bill, Marius (VerfasserIn) , Wurm, Alexander Arthur (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 20 October 2025
In: Cell death discovery
Year: 2025, Jahrgang: 11, Heft: 1, Pages: 1-13
ISSN:2058-7716
DOI:10.1038/s41420-025-02810-4
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41420-025-02810-4
Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41420-025-02810-4
Volltext
Verfasserangaben:Sandra Kuechler, Silke Brilloff, Silvia Schaefer, Elahe Rahimian, Vida Kufrin, Shraddha S. Peri, Julian Musa, Thomas G. P. Gruenewald, Denis M. Schewe, Claudia R. Ball, Martin Bornhaeuser, Hanno Glimm, Marius Bill and Alexander A. Wurm

MARC

LEADER 00000naa a2200000 c 4500
001 1960971271
003 DE-627
005 20260213110809.0
007 cr uuu---uuuuu
008 260213s2025 xx |||||o 00| ||eng c
024 7 |a 10.1038/s41420-025-02810-4  |2 doi 
035 |a (DE-627)1960971271 
035 |a (DE-599)KXP1960971271 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 32  |2 sdnb 
100 1 |a Küchler, Sandra  |e VerfasserIn  |0 (DE-588)1390093387  |0 (DE-627)1960970453  |4 aut 
245 1 0 |a Cell cycle regulator MYBL2 is a distinct vulnerability in acute myeloid leukemia  |c Sandra Kuechler, Silke Brilloff, Silvia Schaefer, Elahe Rahimian, Vida Kufrin, Shraddha S. Peri, Julian Musa, Thomas G. P. Gruenewald, Denis M. Schewe, Claudia R. Ball, Martin Bornhaeuser, Hanno Glimm, Marius Bill and Alexander A. Wurm 
264 1 |c 20 October 2025 
300 |b Illustrationen 
300 |a 13 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 13.02.2026 
520 |a Acute myeloid leukemia (AML) is a hematologic malignancy characterized by the accumulation of myeloid blasts in the bone marrow. Despite the availability of potential curative treatments, patients frequently experience unfavorable outcomes. One crucial aspect contributing to relapse is the plasticity of leukemic clones, which enables them to switch between active proliferation and dormancy. The adaptability of AML underscores the need for novel therapies targeting AML-specific proteins. To address this, genome-wide CRISPR screens can be utilized to identify cancer entity-specific vulnerabilities. Leveraging publicly available functional genomics datasets and comparing AML with non-AML cancer cell lines, we identified a significant dependency on the cell cycle-regulating gene MYBL2 in AML. We describe MYBL2 as a key driver of AML cell growth and proliferation, highlighting its established role as a cell cycle regulator. Also, our findings uncover its previously unrecognized function as an inhibitor of cellular senescence. A knockdown of MYBL2 induces cell cycle arrest in the G2/M phase with subsequent induction of apoptosis in vitro, and reduces leukemic burden in a patient-derived xenograft (PDX) model in vivo. Interestingly, some AML cells evade apoptosis and enter a senescent-like phenotype upon MYBL2-knockdown, which is reversible upon re-expression of MYBL2. Finally, analyses of clinical data from two publicly available patient cohorts demonstrate a lower probability of survival in patients with higher MYBL2 expression, further hinting at the potential relevance of MYBL2 in AML. In conclusion, our findings demonstrate the essential role of MYBL2 in AML, governing the balance between cell proliferation, cell survival and senescence, ultimately influencing the fate of AML cells. 
650 4 |a B-MYB 
650 4 |a CANCER 
650 4 |a ESCAPE 
650 4 |a EXPRESSION 
650 4 |a FAMILY 
650 4 |a GENES 
650 4 |a PROGNOSTIC MARKER 
650 4 |a SENESCENCE 
700 1 |a Brilloff, Silke  |e VerfasserIn  |4 aut 
700 1 |a Schäfer, Silvia Maria  |d 1994-  |e VerfasserIn  |0 (DE-588)1364853086  |0 (DE-627)1924941821  |4 aut 
700 1 |a Rahimian, Elahe  |e VerfasserIn  |4 aut 
700 1 |a Kufrin, Vida  |e VerfasserIn  |0 (DE-588)1380790484  |0 (DE-627)1940279488  |4 aut 
700 1 |a Peri, Shraddha S.  |e VerfasserIn  |4 aut 
700 1 |a Musa, Julian  |d 1992-  |e VerfasserIn  |0 (DE-588)1218049243  |0 (DE-627)1733515569  |4 aut 
700 1 |a Grünewald, Thomas G. P.  |d 1980-  |e VerfasserIn  |0 (DE-588)13673426X  |0 (DE-627)585870365  |0 (DE-576)301246432  |4 aut 
700 1 |a Schewe, Denis M.  |e VerfasserIn  |4 aut 
700 1 |a Ball, Claudia R.  |e VerfasserIn  |0 (DE-588)133777294  |0 (DE-627)691804028  |0 (DE-576)300093799  |4 aut 
700 1 |a Bornhaeuser, Martin  |e VerfasserIn  |4 aut 
700 1 |a Glimm, Hanno  |d 1967-  |e VerfasserIn  |0 (DE-588)113880677  |0 (DE-627)51985120X  |0 (DE-576)289777879  |4 aut 
700 1 |a Bill, Marius  |e VerfasserIn  |4 aut 
700 1 |a Wurm, Alexander Arthur  |d 1984-  |e VerfasserIn  |0 (DE-588)1147777314  |0 (DE-627)1007178442  |0 (DE-576)496030884  |4 aut 
773 0 8 |i Enthalten in  |t Cell death discovery  |d London : Nature Publishing Group, 2015  |g 11(2025), 1, Artikel-ID 470, Seite 1-13  |h Online-Ressource  |w (DE-627)843856351  |w (DE-600)2842546-7  |w (DE-576)453320880  |x 2058-7716  |7 nnas  |a Cell cycle regulator MYBL2 is a distinct vulnerability in acute myeloid leukemia 
773 1 8 |g volume:11  |g year:2025  |g number:1  |g elocationid:470  |g pages:1-13  |g extent:13  |a Cell cycle regulator MYBL2 is a distinct vulnerability in acute myeloid leukemia 
856 4 0 |u https://doi.org/10.1038/s41420-025-02810-4  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext  |7 0 
856 4 0 |u https://www.nature.com/articles/s41420-025-02810-4  |x Verlag  |z kostenfrei  |3 Volltext  |7 0 
951 |a AR 
992 |a 20260213 
993 |a Article 
994 |a 2025 
998 |g 113880677  |a Glimm, Hanno  |m 113880677:Glimm, Hanno  |p 11 
998 |g 13673426X  |a Grünewald, Thomas G. P.  |m 13673426X:Grünewald, Thomas G. P.  |d 910000  |d 912000  |d 910000  |d 950000  |d 950900  |e 910000PG13673426X  |e 912000PG13673426X  |e 910000PG13673426X  |e 950000PG13673426X  |e 950900PG13673426X  |k 0/910000/  |k 1/910000/912000/  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |p 8 
998 |g 1218049243  |a Musa, Julian  |m 1218049243:Musa, Julian  |p 7 
999 |a KXP-PPN1960971271  |e 4915856356 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"person":[{"role":"aut","display":"Küchler, Sandra","given":"Sandra","family":"Küchler"},{"family":"Brilloff","given":"Silke","role":"aut","display":"Brilloff, Silke"},{"display":"Schäfer, Silvia Maria","role":"aut","given":"Silvia Maria","family":"Schäfer"},{"given":"Elahe","family":"Rahimian","display":"Rahimian, Elahe","role":"aut"},{"family":"Kufrin","given":"Vida","role":"aut","display":"Kufrin, Vida"},{"role":"aut","display":"Peri, Shraddha S.","family":"Peri","given":"Shraddha S."},{"family":"Musa","given":"Julian","display":"Musa, Julian","role":"aut"},{"display":"Grünewald, Thomas G. P.","role":"aut","family":"Grünewald","given":"Thomas G. P."},{"family":"Schewe","given":"Denis M.","display":"Schewe, Denis M.","role":"aut"},{"family":"Ball","given":"Claudia R.","display":"Ball, Claudia R.","role":"aut"},{"given":"Martin","family":"Bornhaeuser","display":"Bornhaeuser, Martin","role":"aut"},{"display":"Glimm, Hanno","role":"aut","given":"Hanno","family":"Glimm"},{"family":"Bill","given":"Marius","role":"aut","display":"Bill, Marius"},{"given":"Alexander Arthur","family":"Wurm","display":"Wurm, Alexander Arthur","role":"aut"}],"note":["Gesehen am 13.02.2026"],"id":{"eki":["1960971271"],"doi":["10.1038/s41420-025-02810-4"]},"physDesc":[{"noteIll":"Illustrationen","extent":"13 S."}],"relHost":[{"disp":"Cell cycle regulator MYBL2 is a distinct vulnerability in acute myeloid leukemiaCell death discovery","id":{"eki":["843856351"],"zdb":["2842546-7"],"issn":["2058-7716"]},"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"title":[{"title":"Cell death discovery","title_sort":"Cell death discovery"}],"pubHistory":["1 (2015)-"],"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 19. September 2016"],"part":{"pages":"1-13","volume":"11","extent":"13","year":"2025","text":"11(2025), 1, Artikel-ID 470, Seite 1-13","issue":"1"},"recId":"843856351","name":{"displayForm":["Cell Death Differentiation Association"]},"origin":[{"publisherPlace":"London","dateIssuedDisp":"July 2015-","publisher":"Nature Publishing Group"}]}],"name":{"displayForm":["Sandra Kuechler, Silke Brilloff, Silvia Schaefer, Elahe Rahimian, Vida Kufrin, Shraddha S. Peri, Julian Musa, Thomas G. P. Gruenewald, Denis M. Schewe, Claudia R. Ball, Martin Bornhaeuser, Hanno Glimm, Marius Bill and Alexander A. Wurm"]},"origin":[{"dateIssuedDisp":"20 October 2025","dateIssuedKey":"2025"}],"title":[{"title":"Cell cycle regulator MYBL2 is a distinct vulnerability in acute myeloid leukemia","title_sort":"Cell cycle regulator MYBL2 is a distinct vulnerability in acute myeloid leukemia"}],"recId":"1960971271"} 
SRT |a KUECHLERSACELLCYCLER2020